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enrollment after the index date. Medication possession ratio
(MPR) was calculated as the ratio of total days supply of statins
to the total days during the ﬁrst year after the index date (initial
use period). Statin noncompliance was deﬁned as having a MPR
less than 80%. The outcome was hospitalization during the year
following the initial use period. Association of statin noncom-
pliance in the initial use period to subsequent hospitalization was
examined by multiple logistic regression, controlling for age,
gender, region, comorbidity, prior hospital admission and
number of drug therapeutic classes in the initial use period.
RESULTS: A total of 3063 subjects met the inclusion criteria and
were included in the analysis. A total of 1170 (38.2%) had a
MPR less than 80% in the initial use period. Compared with
patients who were compliant to statins, noncompliant patients
were about 40% more likely to have a subsequent hospitaliza-
tion (OR: 1.37; 95% CI, 1.13–1.65). Other factors associated
with signiﬁcantly higher risk of subsequent hospitalization
included female gender, older age, higher Charlson comorbidity
index score, higher number of drug therapeutic classes, and prior
hospitalization in the use period. CONCLUSIONS: Statin non-
compliance in the year after CHD hospitalization was common
among new statin users and associated with higher risk of sub-
sequent hospitalization. These ﬁndings suggest that interventions
to improve compliance could reduce risk for hospitalization.
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OBJECTIVE: To identify key drivers of non-persistence on
therapy, using multivariate regression techniques, based on IMS
Disease Analyzer Germany (DA) data. METHODS: DA is a lon-
gitudinal patient database containing de-identiﬁed patient
records collected from 400 practices (290 GPs and 110 Internal
Specialists) treating currently +/-1.3 million patients. We identi-
ﬁed a cohort of hypertensive patients being prescribed valsartan,
metoprolol, ramipril, enalapril, lisonopril, amlodipine or
hydrochlorothiazide (HCTZ), within the period 2003–2004.
Patients had at least 12 months of data prior to, and following
their index date (date of ﬁrst prescription of the study drug
within the window). History of hypertension was deﬁned as the
difference between diagnosis date and index date. Patients who
start on monotherapy of study drugs and those who start on
combination therapy involving at least one of the study drugs
were analyzed separately. Medication persistence was deﬁned as
the total time on a drug, from initiation of therapy to the end of
the last supplied prescription for that drug without intervening
discontinuation. RESULTS: A total of 42,991 patients were
analysed, of whom 61.7% discontinued study medication within
12 months post-index. Cox-regression showed that heart failure
(Hazard Rate to discontinue therapy; HR = 1.04), renal disease
(HR = 1.072), and not being treated with valsartan (HR = 1.07
to 1.359) independently and signiﬁcantly increased the proba-
bility of being non-persistent. Older age (HR = 0.998 per year),
male gender (HR = 0.948), >6mo history of hypertension (HR
= 0.87), dyslipidemia (HR = 0.96), recent stroke (HR = 0.891),
and receiving combination therapy (HR = 0.92) were signiﬁ-
cantly associated with improved persistence. CONCLUSION:
Different demographic and clinical factors are independently
associated with persistence to antihypertensive therapy. Patients
on valsartan were 7 to 36% more likely to persist compared to
patients taking other frequently used antihypertensive medica-
tions. Considering such factors is important to identify patients
most likely to discontinue therapy and to avoid achieving sub-
optimal therapeutic outcomes.
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OBJECTIVES: To compare several adherence metrics across dif-
ferent therapeutic conditions, which might complicate these
associations. METHODS: Plan participants dispensed lipid low-
ering, antihypertensive, or selective serotonin reuptake inhibitor
between January 1, and June 30, 2004, had their same class pre-
scriptions extracted for six months before and one year after
their ﬁrst prescription from a large deidentiﬁed US prescription
database. Lipid-lowering (n = 102,067), antihypertensive (n =
139,333), and SSRIs (n = 99,439) plan participants without a
same-class prescription in the pre-period had: number of 
prescriptions—prescription count adjusting 3–1 for mail-retail;
persistent period—ﬁrst minus last ﬁll date; length of exposure—
persistent period plus days supply on last prescription; total
days—sum of all days supply; unique days—sum of days with
exposure to drug; medication possession ratio—sum of days
supply divided by length of exposure (variable) or study period
(ﬁxed); proportion of unique days—sum of days with exposure
divided by length of exposure (variable) or study period (ﬁxed);
and continuous days—days spanned before a break in therapy
calculated over the post-period. Results for these adherence
metrics were divided into equal parts for comparisons.
RESULTS: The measures were grouped into: 1) MPR variable
and PUD variable, 2) unique days 3) MPR ﬁxed, PUD ﬁxed, total
days, length of exposure, and number of prescriptions; 4) per-
sistent period; 5) continuous days. Differences among the groups
started within the ﬁrst 30 days, with group 1 having values less
than 1 percent and the continuous group having more than 20%.
Groups 1 and 2 remained lower than the other groups ending at
about 50% while the others ended at about 70%. CONCLU-
SIONS: Differences in how adherence is calculated needs to be
considered when estimating beneﬁts. Other metrics that account
for dose changes, concomitancy, and other complex regimens
may need further exploration.
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OBJECTIVE: Niacin is highly effective in raising HDL-C, while
lowering LDL-C and triglycerides. However, niacin induced
cutaneous ﬂushing may limit patient acceptance. We compared
the persistency with newly-initiated ER niacin versus other lipid
modifying drug (LMD) classes in recent clinical practice.
METHODS: Administrative claims from the Ingenix Lab/Rx
DatabaseTM were used to identify patients aged >20 years who
were new users (i.e. no prescription from the same LMD class
in the pervious 1-year) of statins, ER niacin, ﬁbrates, bile acid
sequestrants (BAS), or ezetimibe between January 1, 2001 and
June 30, 2003 and were continuously enrolled for 1 year after
LMD initiation. The proportion of days covered (PDC) with
each LMD class was calculated in each quarter (1Q–4Q) and
over the 1-year period after therapy initiation. Patients were
deﬁned as persistent if PDC >= 80%. Generalized linear models
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with generalized estimating equations were used to estimate the
odds of being persistent for each LMD class relative to statins
while controlling for patient, plan, and prescription characteris-
tics. RESULTS: The overall proportion of patients persistent to
therapy in the 1 year after therapy initiation was 11% for BAS
(N = 9853), 25% for ER niacin (N = 9404), 32% for ﬁbrates (N
= 21,004), 39% for statins (N = 105,178), and 44% for eze-
timibe (N = 974). The proportion of patients who were persis-
tent with ER niacin therapy declined from 44% to 30%, 27%,
and 24% over the ﬁrst four quarters after therapy initiation. Sim-
ilarly, mean PDC for niacin was 68% in Q1, 43% in Q2, 36%
in Q3, and 32% in Q4 of the 1 year after therapy initiation.
Excepting ezetimibe, multivariate analyses conﬁrmed signiﬁ-
cantly lower odds of persistence on all LMD classes relative to
statins (p < 0.001). CONCLUSION: Excepting BAS, we found
that ER niacin had the lowest persistence among all LMD
classes. Since long-term treatment is generally necessary in
persons with dyslipidemia, suboptimal persistence may affect the
overall success of LMD therapy.
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OBJECTIVE: To evaluate the effect of a new program that
allowed patients to ﬁll 90-day prescriptions in retail pharmacies.
METHODS: The research is a case-control natural experiment.
A total of 38,852 patients in the treatment cohort received drug
beneﬁt through a managed care organization that initiated a 
90-day supply retail option in January 1, 2005. Patients were
evaluated if they used agents to treat diabetes, dyslipidemia, or
hypertension and were continuously eligible for beneﬁt for 18
months—9 months pre- and post-January 1, 2005. The control
cohort comprised 49,738 patients who were insured in the same
managed care organization, and used the same drugs and were
followed for the same length of time the year before and after
January 1, 2004. Treatment and control patients were matched
on a number of dimensions—including demographic character-
istics, copays, and baseline drug consumption—using the
weighted sum of absolute case-control differences. The effect of
the new 90-day retail program was then evaluated with the
matched sample using the difference-in-differences estimator.
Two outcomes were evaluated: the number of prescription in the
above therapeutic classes and the duration of supply. RESULTS:
The introduction of 90-day dispensing at retail allowed patients
to reduce the number of prescription they ﬁlled by an average of
1.2 for diabetes, 2.2 for antilipidemics, and 4.0 for antihyper-
tensives. Despite this reduction, actual total drug supply
increased as the average length of supply per prescription
increased. Total supply increased by 4.3 days for antihyperten-
sives, 11.5 days for antilipidemics, and by 75.3 days for diabetes.
CONCLUSION: Reactions to the introduction of a new retail
dispensing option demonstrate that dispensing ﬂexibility is valu-
able to the patients and can lead to improvement in compliance,
presumably because reﬁlling a prescription every 30 days can be
burdensome.
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WITH AT LEAST 50%.
Penning-van Beest FJ1, Goettsch WG2, Klungel OH3, Kastelein JJ4,
Herings RM2
1PHARMO Institute, Utrecht,The Netherlands, 2PHARMO Institute,
Utrecht,The Netherlands, 3Universiteit Utrecht, Utrecht,The
Netherlands, 4Academisch Medisch Centrum, Amsterdam,The
Netherlands
OBJECTIVES: We investigated the “real world” effectiveness of
statin therapy, focusing on the effect of dose and early treatment
discontinuation on the risk for acute myocardial infarction
(AMI). METHODS: Data were obtained from the PHARMO
Record Linkage System including among others linked drug-dis-
pensing records and hospital records for over two million indi-
viduals of the Netherlands. New users of statins in the period
January 1 1991 until December 31 2004, °Y´18 years of age were
included in the study cohort. Exposure to statins, both in terms
of persistence and dose, was determined over the ﬁrst two treat-
ment years. To determine the risk for AMI, patients were fol-
lowed from this two-year time point until the ﬁrst hospital
admission for AMI, death, or end of the study period (Decem-
ber 31, 2004), whichever was earliest. Patients were classiﬁed
into two groups according to their risk of cardiovascular disease
at the start of outcome follow-up. RESULTS: The study cohort
included 46,332 low-risk statin users (78%) and 12,762 high-
risk statin users (22%). 31,557 patients (53%) discontinued
statin use within two years. 20,883 patients (35%) were persis-
tent statin users with an average equipotent dose °Y´4. A 40%
reduction in risk of AMI with two-year persistent statin use was
observed in low- and high-risk users. The protective effect of
statin use increased with a higher equipotent dose; a 25% reduc-
tion in risk of AMI with an average equipotent dose °Ü3 and a
60% risk reduction with an average equipotent dose °Y´4. CON-
CLUSION: The results show that statins are suboptimally dosed
in real life and used too short for having the maximum beneﬁt
in terms of preventing AMI. Our ﬁndings corroborate ﬁndings
from clinical trials insofar that the longer patients are treated 
and the higher the dose, the more successful the prevention of
AMI.
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OBJECTIVES: While managed care data can be used to assess
medication compliance and persistence, these databases gener-
ally do not permit observation of long-term outcomes. We there-
fore applied modeling techniques to explore the impacts of
compliance and persistence with hypertension therapy on long-
term cardiovascular outcomes among managed care hyperten-
sion patients. METHODS: We analyzed 12-month blood
pressure (BP) and compliance/persistence using data for hyper-
tension patients receiving valsartan therapy from the Geisinger
Clinic, a U.S. regional healthcare network. Long-term cardio-
vascular outcomes (myocardial infarction, stroke, coronary
artery bypass, angioplasty, and cardiovascular death) were based
on algorithms from the Physicians’ Health Study (13 years
follow-up) and Women’s Health Study (7 years) as presented by
Glynn et al. (2002). No signiﬁcant differences were observed
